ZECUITY Drug Patent Profile

When do Zecuity patents expire, and when can generic versions of Zecuity launch?

Zecuity is a drug marketed by Teva Branded Pharm and is included in one NDA. There are nine patents protecting this drug.

This drug has ninety-two patent family members in fourteen countries.

The generic ingredient in ZECUITY is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zecuity

A generic version of ZECUITY was approved as sumatriptan succinate by HIKMA on February 6^th, 2009.

Summary for ZECUITY

International Patents:	92
US Patents:	9
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZECUITY

ZECUITY is protected by nine US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No	7,973,058
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No	9,327,114		Y
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No	8,470,853
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No	8,597,272		Y

International Patents for ZECUITY

See the table below for patents covering ZECUITY around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2603274
China	100486656
Canada	2727927	PHARMACOCINETIQUE D'UNE ADMINISTRATION IONTOPHORETIQUE DE SUMATRIPTAN (PHARMACOKINETICS OF IONTOPHORETIC SUMATRIPTAN ADMINISTRATION)
New Zealand	596498	Transdermal methods and systems for the delivery of anti-migraine compounds

Last updated: February 7, 2026

What Is ZECUITY and How Does It Fit in the Market?

ZECUITY is a transdermal patch delivering sumatriptan for acute migraine treatment. It was developed by US WorldMeds and approved by the FDA in 2016. The drug’s primary advantage is rapid absorption through the skin, providing an alternative to oral and injectable forms of sumatriptan.

What Are the Market Dynamics for ZECUITY?

The migraine market focuses on acute treatment, with global sales expected to reach approximately $5 billion by 2027[1]. Key competitors include oral triptans, nasal sprays, and injectable forms. ZECUITY faces competition due to:

• Adoption barriers: Patient preference leans toward oral forms.
• Cost considerations: Patch formulation is more expensive than generics or cheaper routes.
• Limited indication scope: Approved only for acute migraine, not preventive use.

Despite these challenges, increased awareness of non-oral delivery methods and patient preference for convenience could support niche growth.

What Are the Key Investment Drivers for ZECUITY?

1. Market Penetration Potential
   ZECUITY targets migraine patients who experience gastrointestinal issues or nausea, which impair oral medication absorption. The tech’s non-invasive nature may appeal to this subset, representing an estimated 25% of migraine sufferers[2].

2. Brand Positioning and Pipeline
   US WorldMeds continues to promote ZECUITY and explore pipeline extensions for other drugs in patch form, potentially expanding indications or revising technology for broader neurological indications.

3. Pricing and Reimbursement
   The patch’s premium pricing may influence adoption. Reimbursement challenges exist, particularly in cost-sensitive markets. Internal negotiations with payers will be critical.

4. Regulatory and Clinical Data
   Ongoing post-marketing surveillance and clinical studies remain crucial. Efficacy comparable to injections and a favorable safety profile support market confidence.

What Are the Financial and Commercial Risks?

• Market share capture depends on overcoming patient and physician reluctance to switch from existing treatments.
• Limited approved indications restrict revenue streams.
• Competition from generics and newer CGRP inhibitors (e.g., erenumab, fremanezumab) threaten ZECUITY’s position.

What Is the Investment Outlook?

The product has niche appeal but limited blockbuster potential absent expanded indications. The primary growth route involves targeting unmet needs within the migraine population, expanding through pipeline innovations, and navigating reimbursement landscapes.

Investors should consider:

• Current sales figures: No detailed public revenue data available. Presumed modest until wider adoption.
• Strategic initiatives: Pipeline development and market expansion strategies are crucial.
• Competitive landscape: CGRP antagonists are gaining market share; ZECUITY must differentiate itself.

Key Takeaways

ZECUITY is a transdermal sumatriptan patch approved for acute migraines. Its appeal lies in non-invasive delivery for patients with gastrointestinal issues. Market penetration faces regulatory, cost, and competitive barriers. Growth prospects rely on broader adoption within a niche segment and pipeline expansion, balanced against competitive pressure from oral and injectable treatments and emerging CGRP therapies.

FAQs

1. What is the primary advantage of ZECUITY over traditional sumatriptan treatments?
It offers a non-invasive, rapid-absorption delivery directly through the skin, beneficial for patients with nausea or gastrointestinal issues.

2. How significant is the market for transdermal migraine treatments?
It is a small but growing segment, with estimates placing the overall migraine market at around $5 billion globally by 2027[1].

3. What are the main barriers to ZECUITY's market growth?
Patient preference for oral medications, higher costs, limited indications, and competition from generic and newer therapies.

4. How does ZECUITY compare to CGRP inhibitors?
CGRP inhibitors target migraine prevention, while ZECUITY treats acute episodes. The latter faces competition from these inhibitors for both efficacy and cost-effectiveness in acute treatment.

5. What is the outlook for pipeline developments related to ZECUITY?
Further indications, improved delivery methods, and new drugs in patch form could expand its market niche, contingent upon clinical success and regulatory approval.

---

References [1] Markets and Markets. "Migraine Drugs Market Forecast," 2022.
[2] American Migraine Foundation. "Migraine Statistics," 2021.